Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants
mBio · 16.10.2024 · 15 (10)
DOI: 10.1128/mbio.03220-23 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift mBio, erschienen am 16.10.2024. Verfasst von Hisano Yajima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Spike Glycoprotein, Coronavirus, Evolution, Molecular. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED | ASPIRE Program, AMED | SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers "UTOPIA", AMED | SCARDA Program on R&D of new generation vaccine including new modality application.
Abstract (Originalsprache)
Due to the incessant emergence of various SARS-CoV-2 variants with enhanced fitness in the human population, controlling the COVID-19 pandemic has been challenging. Understanding how the virus enhances its fitness during a pandemic could offer valuable insights for more effective control of viral epidemics. In this manuscript, we review the evolution of SARS-CoV-2 from early 2022 to the end of 2023—from Omicron BA.2 to XBB descendants. Focusing on viral evolution during this period, we provide concrete examples that SARS-CoV-2 has increased its fitness by enhancing several functions of the spike (S) protein, including its binding affinity to the ACE2 receptor and its ability to evade humoral immunity. Furthermore, we explore how specific mutations modify these functions of the S protein through structural alterations. This review provides evolutionary, molecular, and structural insights into how SARS-CoV-2 has increased its fitness and repeatedly caused epidemic surges during the pandemic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, Kyoto, Japan.
- Laboratory of Biomolecular Science and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
- Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
- Faculty of Liberal Arts, Sophia University, Tokyo, Japan.
- Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
- Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan.
ORCID-Profile: Hisano Yajima, Tomo Nomai, Jumpei Ito, Takao Hashiguchi, Kei Sato
Förderung
- AMED | ASPIRE Program
- AMED | SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers "UTOPIA"
- AMED | SCARDA Program on R&D of new generation vaccine including new modality application
- AMED | SCARDA Kyoto University Immunomonitoring Center (KIC)
- AMED | SCARDA Hokkaido University Institute for Vaccine Research and Development (HU-IVReD)
- AMED | BINDS
- AMED | CREST
- AMED | Research Program on Emerging and Re-emerging Infectious Diseases
Zitieren
APA
Yajima, H., Nomai, T., Okumura, K., Maenaka, K., Genotype to Phenotype Japan (G2P-Japan) Consortium, Ito, J., Hashiguchi, T., & Sato, K. (2024). Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants. mBio, 15(10). https://doi.org/10.1128/mbio.03220-23
Vancouver
Yajima H, Nomai T, Okumura K, Maenaka K, Genotype to Phenotype Japan (G2P-Japan) Consortium, Ito J, et al. Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants. mBio. 2024;15(10). doi:10.1128/mbio.03220-23
BibTeX
@article{Yajima2024,
author = {Yajima, Hisano and Nomai, Tomo and Okumura, Kaho and Maenaka, Katsumi and Genotype to Phenotype Japan (G2P-Japan) Consortium, Genotype to Phenotype Japan (G2P-Japan) Consortium and Ito, Jumpei and Hashiguchi, Takao and Sato, Kei},
title = {Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants},
journal = {mBio},
year = {2024},
volume = {15},
number = {10},
doi = {10.1128/mbio.03220-23}
}
EUVIMED